"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors. [PDF]
HaematologicaGrainger BT, Cheah CY.
europepmc +1 more source
Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia [PDF]
, 2018 AG Evans +18 more
core +1 more source
Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy. [PDF]
Ther Adv Neurol DisordShirani A +6 more
europepmc +1 more source
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. [PDF]
Ann HematolYang P +6 more
europepmc +1 more source
BTK inhibitors in CLL: second-generation drugs and beyond. [PDF]
Blood AdvTam C, Thompson PA.
europepmc +1 more source
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma [PDF]
, 2017 core +1 more source
[Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma]. [PDF]
Zhonghua Xue Ye Xue Za ZhiLu JB +9 more
europepmc +1 more source
Identification of Potential Nontoxic Human <i>BTK</i> Inhibitors through an Integrated Deep Learning and Structure-Based Drug Repositioning Strategy. [PDF]
ACS OmegaIqbal MW, Sun X, Yuan Q.
europepmc +1 more source
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]
, 2018 et al, +2 more
core +1 more source